Paul Reilly

26.5k citations
128 papers · 17.5k indexed · 5 hit papers · h-index 42

Impact in

    • Venous Thromboembolism Diagnosis and Management
    • Atrial Fibrillation Management and Outcomes
    • Cardiac Arrhythmias and Treatments
    • Antiplatelet Therapy and Cardiovascular Diseases
    • Cardiac electrophysiology and arrhythmias
    • Acute Myocardial Infarction Research

Papers in

    • Venous Thromboembolism Diagnosis and Management 35
    • Atrial Fibrillation Management and Outcomes 89
    • Cardiac Arrhythmias and Treatments 34
    • Acute Myocardial Infarction Research 17
    • Antiplatelet Therapy and Cardiovascular Diseases 16
    • Cardiac electrophysiology and arrhythmias 7

Paul Reilly

126 papers receiving 16.8k citations

Hit Papers

The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients 2013 · 630 citations
63020092026201420202.5k5.0k7.5k

Peers

Paul Reilly
Comparison fields: 5 of 126
  • Internal Medicine 7.8k
  • Cardiology and Cardiovascular Medicine 15.7k
  • Epidemiology 2.4k
  • Hematology 692
  • Toxicology 210
Replace Jonas Oldgren with:
Jonas Oldgren Sweden
Marco Alings Netherlands
Werner Hacke Germany
Scott D. Berkowitz United States
Rafael Díaz Argentina
Basil S. Lewis Israel
Christopher C. Nessel United States
Campbell Joyner Canada
Jun Zhu China
Denis Xavier India
Paul Reilly relative to Jonas Oldgren Sweden Jonas Oldgren's profile →
Citations per field
00.5×1.5×
Jonas Oldgren · 1×
Citations per year

Countries citing papers authored by Paul Reilly

Since Specialization
Citations

This map shows the geographic impact of Paul Reilly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Reilly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Reilly more than expected).

Fields of papers citing papers by Paul Reilly

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Reilly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Reilly. The network helps show where Paul Reilly may publish in the future.

Co-authors

The 25 scholars most cited alongside Paul Reilly, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Paul Reilly Line = papers co-authored together Paul Reilly links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20168
2 20161
3
Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions
20152
4
Initial experience with idarucizumab in dabigatran-treated patients requiring emergency surgery or interventon: interim results from the RE-VERSE AD study
20155
5 201412
6 201368
7
Benefits of Dabigatran versus Warfarin in Hypertensive Patients With Atrial Fibrillation : Results From The Re-ly Trial
20131
8
Abstract 17765: A Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Healthy Male Volunteers
201341
9
The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients
Hit paper breakdown →
2013630
10
Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin
Hit paper breakdown →
2012399
11 2012313
12 2012344
13 2012304
14 2012112
15
Randomized Comparison of the Effects of Two Doses of Dabigatran Etexilate on Clinical Outcomes Over 4.3 Years : Results of the Rely-Able Double-Blind Randomized Trial
20126
16 20112
17
Abstract 18321: D-dimer is Prognostic for Stroke, Major Bleeding and Death During Anticoagulation of Atrial Fibrillation - a RELY Substudy
20102
18 20102
19
Abstract 13472: NT-proBNP is Prognostic for Stroke and Death in Atrial Fibrillation - a RELY Substudy
20103
20 19884

About Paul Reilly

Paul Reilly is a scholar working on Internal Medicine, Cardiology and Cardiovascular Medicine, Rehabilitation, Toxicology and Pharmacology, having authored 128 papers that have together received 17.5k indexed citations. Recurring topics across this work include Atrial Fibrillation Management and Outcomes (89 papers), Venous Thromboembolism Diagnosis and Management (35 papers), Cardiac Arrhythmias and Treatments (34 papers), Acute Myocardial Infarction Research (17 papers), Antiplatelet Therapy and Cardiovascular Diseases (16 papers), Cardiac electrophysiology and arrhythmias (7 papers), Heparin-Induced Thrombocytopenia and Thrombosis (6 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). The work is most often cited by research in Internal Medicine (7.8k citations), Cardiology and Cardiovascular Medicine (15.7k citations), Epidemiology (2.4k citations), Hematology (692 citations) and Toxicology (210 citations). Paul Reilly has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Stuart J. Connolly, Michael D. Ezekowitz, Salim Yusuf, Lars Wallentin, Jonas Oldgren, John W. Eikelboom, Marco Alings, Susan Wang, Jeanne Varrone and Janice Pogue. Their work appears in journals such as Circulation, Journal of the American College of Cardiology, American Heart Journal, Thrombosis and Haemostasis and Journal of Thrombosis and Haemostasis.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026